Rasagiline for Parkinson’s Disease
The FDA has approved the molecular entity rasagiline (Agilect, Azilect, Teva Pharmaceuticals, Israel) for the treatment of Parkinson’s disease. The drug is a monoamine oxidase type-B inhibitor that blocks the breakdown of dopamine. Dopamine sends information to the parts of the brain that control movement and coordination.
Parkinson’s disease is caused by the destruction of the brain cells that produce dopamine. As dopamine levels decline, patients become incapable of initiating and controlling movements.
olanzapine tablets
Rasagiline may be associated with hypertensive crisis if patients also consume tyramine-rich foods or beverages (e.g., cheese, red wine) or dietary supplements or amines contained in many cough and cold medications.
